Athersys Inc (ATHX)

2.06
NASDAQ : Health Care
Prev Close 2.06
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.94 / 2.90
Avg Volume 287.50K
Exchange NASDAQ
Shares Outstanding 84.98M
Market Cap 166.56M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARRS, ATAX, CYRN, DAR, GTIM, MLP, NPTN, RCMT, RDN, SEB, SNE, TISA Downgrades: APEI, ATHX, CFBK, HMHC Initiations: CHCT Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports Second Quarter 2016 Results

Athersys Reports Second Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys Joins Russell 3000® Index

Athersys Joins Russell 3000® Index

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATHX, BMY, HDSN, NX, OEC, PMT Downgrades: ALSK, CENX, CLI, EVR, MLP, PII, UFPT Initiations: BPMC, EVA Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports First Quarter 2016 Results

Athersys Reports First Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys (ATHX) Strong On High Relative Volume Today

Athersys (ATHX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Athersys (ATHX) as a strong on high relative volume candidate

Athersys Reports Fourth Quarter And 2015 Annual Results

Athersys Reports Fourth Quarter And 2015 Annual Results

Management to Host Conference Call at 4:30pm EST Today

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

About that 17% bump in Athersys' stock price Thursday: Don't be a sucker.

Here’s Why Athersys (ATHX) Stock is Jumping Today

Here’s Why Athersys (ATHX) Stock is Jumping Today

Athersys (ATHX) stock is up after the company announced positive results from the analysis of one year follow-up data from a Phase 2 study of its therapy for ischemic strokes.

One-Year Results From Phase 2 Stroke Study Of MultiStem® Cell Therapy Demonstrate A Significantly Higher Rate Of Complete Or Nearly Full Recovery

One-Year Results From Phase 2 Stroke Study Of MultiStem® Cell Therapy Demonstrate A Significantly Higher Rate Of Complete Or Nearly Full Recovery

Data Presented at 2016 International Stroke Conference Demonstrate Statistically Significant Improvement in Excellent Outcomes When Evaluating All Subjects and Key Subgroups

Athersys' MultiStem® Data To Be Presented At International Stroke Conference 2016

Athersys' MultiStem® Data To Be Presented At International Stroke Conference 2016

Multiple Presentations by Leading Stroke Clinical Investigators

Athersys And Healios Announce R&D Day

Athersys And Healios Announce R&D Day

Special Event to be Held Thursday, February 4, 2016, at the Harvard Club of New York City

Publication Provides Further Confirmation Of The Potential For Athersys' MultiStem® Cell Therapy To Provide Benefit In Acute Neurological Injury

Publication Provides Further Confirmation Of The Potential For Athersys' MultiStem® Cell Therapy To Provide Benefit In Acute Neurological Injury

Study Demonstrates Stem Cell Therapy Provides Significant Benefit in Hypoxic-Ischemic Injury Model in Large Animal Model

Athersys (ATHX) Stock Advances on Healios Licensing Agreement

Athersys (ATHX) Stock Advances on Healios Licensing Agreement

Athersys (ATHX) stock is surging after the company announced a license agreement with Healios for treatment of strokes.

Healios And Athersys Enter Into Regenerative Medicine Partnership For Treatment Of Stroke Using MultiStem® Therapy

Healios And Athersys Enter Into Regenerative Medicine Partnership For Treatment Of Stroke Using MultiStem® Therapy

Alliance to Focus on Development and Commercialization of Regenerative Medicine Products for Stroke and Other Potential Indications Using New Regulatory Framework in Japan

Athersys Reports Third Quarter 2015 Results

Athersys Reports Third Quarter 2015 Results

Management to Host Conference Call at 4:30 pm EST Today

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look poised to break out and trade higher from current levels.

Athersys Reports Second Quarter 2015 Results

Athersys Reports Second Quarter 2015 Results

Management to Host Conference Call at 4:30pm EDT Today